TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03712384

Intervention type: OTHER
Intervention: Semi structured face to face interview
Description: Face-to-face semi-structured interview conducted in the hospital, where young adults were hospitalized 10 years before, in a quiet and isolated office. The topic guide was built according to literature review, without further change after pilot test. Interviews where audio-recorded and transcribed
Study: NCT00579449

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Families Durham
Description: Implementation of Healthy Families America program plus Parents As Teachers curriculum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Families Durham
Description: Implementation of Healthy Families America program plus Parents As Teachers curriculum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yearly Checkup
Description: Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
Study: NCT02138253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT04376112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist and pillpack intervention
Description: These participants will be randomized into one of the following two cohorts: standard of care (SOC) and pharmacy intervention group (blister packaging + MTM services). For pharmacy intervention (PI) group, the POCT will be used to measure HbA1c and blood pressure (BP) at baseline, 3, and 6 months during medication therapy management (MTM) service. Recommendation from MTM services will be documented in the patients' electronic medical records (EMRs) and shared with their primary care providers. For the SOC group, HbA1c and BP will be measured at the physician's office and researchers will have an access to participants' EMR.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: None. Regular visits to primary care physician. Will measure HbA1c and blood pressure at baseline, 3, and 6 months
Study: NCT01419977

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution, administered by nursing staff once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin
Study: NCT02726477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wuling San
Description: Patients will be administrated with Wuling San at a dosage of 1g/kg twice a day after randomisation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.
Study: NCT04295330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride, Injectable
Description: In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
Study: NCT02782572

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Exercise in acute heart failure in three different groups (conventional medical treatment; exercise with non-invasive ventilation and exercise with placebo of non-invasive ventilation).
Study: NCT02484638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL689
Description: Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptacog alfa (activated)
Description: Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptacog alfa (activated)
Description: Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.
Study: NCT02782572

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Exercise in acute heart failure in three different groups (conventional medical treatment; exercise with non-invasive ventilation and exercise with placebo of non-invasive ventilation).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise in acute heart failure in three different groups (conventional medical treatment; exercise with non-invasive ventilation and exercise with placebo of non-invasive ventilation).
Study: NCT01252056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probucol
Description: 250mg,Bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probucol and Cilostazol
Description: 50-100mg,Bid
Study: NCT00816556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol valerate
Description: Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vanicream Lite
Description: Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
Study: NCT00251264

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open stabilization
Description: Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a T shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic stabilization
Description: With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
Study: NCT02819219

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplemental
Description: participants were provided with either placebo, placebo + ElevATP, or placebo + ElevATP + Caffeine + Vitamins.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplemental
Description: participants were provided with either placebo, placebo + ElevATP, or placebo + ElevATP + Caffeine + Vitamins.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental
Description: participants were provided with either placebo, placebo + ElevATP, or placebo + ElevATP + Caffeine + Vitamins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Concurrent with the supplemental intervention, all subjects participated in a resistance exercise intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Concurrent with the supplemental intervention, all subjects participated in a resistance exercise intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Intervention
Description: Concurrent with the supplemental intervention, all subjects participated in a resistance exercise intervention.
Study: NCT01501227

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taper Guard Endotracheal Tube
Description: comparison of two different endotracheal tubes
Study: NCT00774007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalazine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00179205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepro nutritional supplement
Description: oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
Study: NCT01327313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD525797
Description: Subjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD525797
Description: Subjects will receive 500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD525797
Description: Subjects will receive 1000 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD525797
Description: Subjects will receive 1500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity, or withdrawal of consent.
Study: NCT01797159

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal-sparing Prophylactic Cranial Irradiation
Description: Hippocampal-sparing Prophylactic Cranial Irradiation
Study: NCT00425893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hand hygiene
Description: alcohol-based hand wash

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hand hygiene
Description: alcohol-based hand wash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health education
Description: Proper nutrition, etc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: face masks
Description: face masks
Study: NCT01510535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: First 2 weeks Placebo(2ml) once weekly in experimental group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyruan Plus
Description: Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBSA0103
Description: at third week LBSA0103(60mg) once in experimental group
Study: NCT01333956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 50mg
Description: Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 100mg
Description: Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Study: NCT02129634

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CB-PTA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CB-PTA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB-PTA
Study: NCT03704948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RCT Treatment -Listening Visits delivered by NICU nurse in person
Description: 6 sessions, approximately one hour in length, delivered by a nurse who uses empathic listening and problem solving.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RCT Control Usual mental health care delivered by NICU social workers
Description: RCT Control Usual mental health care delivered by NICU social workers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open trial: Listening Visits delivered by a NICU nurse via zoom
Description: Open trial: Listening Visits delivered by a NICU nurse via zoom
Study: NCT00546455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: 200 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules/day
Study: NCT04547231

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional flow reserve, Coronary CT angiography
Description: 1. Coronary CT angiography (CCTA) and measurement of fractional flow reserve (FFR) will be performed as part of routine clinical practice. The decision to perform CCTA before invasive angiography was at the judgment of the physicians in charge.~2. Physiologic assessment includes delta FFR (lesion-specific) and FFR (vessel-specific) measurement. Delta FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).~3. Stenosis and plaque features on CCTA will be analyzed by an independent CCTA core laboratory (Severance Cardiovascular Hospital, Seoul, Korea), and pericoronary and epicardial fat metrics (fat attenuation index, epicardial fat attenuation index, epicardial fat volume, etc.) will be obtained by an independent cardiac CT fat core laboratory (Tsuchiura Kyodo general hospital, Ibaraki, Japan).

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional flow reserve, Coronary CT angiography
Description: 1. Coronary CT angiography (CCTA) and measurement of fractional flow reserve (FFR) will be performed as part of routine clinical practice. The decision to perform CCTA before invasive angiography was at the judgment of the physicians in charge.~2. Physiologic assessment includes delta FFR (lesion-specific) and FFR (vessel-specific) measurement. Delta FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).~3. Stenosis and plaque features on CCTA will be analyzed by an independent CCTA core laboratory (Severance Cardiovascular Hospital, Seoul, Korea), and pericoronary and epicardial fat metrics (fat attenuation index, epicardial fat attenuation index, epicardial fat volume, etc.) will be obtained by an independent cardiac CT fat core laboratory (Tsuchiura Kyodo general hospital, Ibaraki, Japan).
Study: NCT01676818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study: NCT01507402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033(SAR391786)
Description: Administration method A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033(SAR391786)
Description: Administration method A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033(SAR391786)
Description: Administration method A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033(SAR391786)
Description: Administration method A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033(SAR391786)
Description: Administration method A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033(SAR391786)
Description: Administration method A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033(SAR391786)
Description: Administration method B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033(SAR391786)
Description: Administration method B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033(SAR391786)
Description: Administration method B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (inactive substance)
Study: NCT01501227

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional endotracheal tube
Description: Sham Comparator
Study: NCT01606891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-component/setting parent-targeted intervention
Description: parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
Study: NCT01507402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (inactive substance)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (inactive substance)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (inactive substance)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (inactive substance)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (inactive substance)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (inactive substance)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (inactive substance)
Study: NCT03245463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational handout
Description: The educational handout will include information on self-management strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational handout
Description: The educational handout will include information on self-management strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal script
Description: The verbal script will include details on self-management strategies that will be reviewed with the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.
Study: NCT03517111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/substance use prevention
Description: Parenting program focusing on diet improvement and substance use prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance use prevention only
Description: Parenting program focusing only on substance use prevention

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Academic success program
Description: Program focusing on academic success and college acceptance
Study: NCT00853736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roxicodone™ tablet 30 mg
Description: Roxicodone™ tablet 30 mg, single dose with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride tablet 30 mg
Description: Oxycodone hydrochloride tablet 30 mg, single dose with food
Study: NCT02332083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SR-WBV
Description: Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SR-WBV
Description: Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aktiv Tramp
Description: Participants will undergo a training program set from the 5 to 8 week, three times a week over 4 minutes.
Study: NCT05343208

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EFP Psychometric assessment to determine level of afflication
Description: Patients were asked to complete a psychometric assessment in relation to their psychological wellbeing. Results were presented to the patient and validdated by the patient.
Study: NCT00466089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva®)
Description: Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
Study: NCT00433797

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prostate cancer, phytochemical and PUFA
Description: Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prostate cancer, phytochemical and PUFA
Description: Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prostate cancer, phytochemical and PUFA
Description: Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.